Blood Pressure Management in Stroke Following Endovascular Treatment (DETECT)
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 2
Contacts and Locations
Study Contact
Study Contact
- Name: Aristeidis H Katsanos, MD
- Phone Number: +1-365-888-1441
- Email: ar.katsanos@gmail.com
Study Locations
-
-
Ontario
-
Hamilton, Ontario, Canada, L8L2X2
- Hamilton General Hospital
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Age equal or more than 18 years.
- Eligible for endovascular treatment (EVT) within 24 hours from symptom onset according to current clinical practice.
- Presence of a proximal large vessel occlusion in the anterior circulation, defined as occlusion of the intracranial segment of the internal carotid artery and/or occlusion of the M1 segment or proximal M2 segment of the middle cerebral artery.
- Successful recanalization after the end of the EVT procedure, defined as modified thrombolysis in cerebral ischemia (mTICI) score equal or more than 2b.
- Sustained elevated systolic BP level after recanalization, defined as 2 consecutive systolic BP readings ≥ 150 mmHg (or ≥ 140 mmHg if the participant has a known history of hypertension) taken more than 5 minutes apart.
- Ability of the patient or legal representative to provide informed consent.
- Randomization within 60 minutes from the end of the EVT procedure.
Exclusion Criteria:
- Presence of concomitant ipsilateral or contralateral extracranial vessel occlusion or remaining stenosis ≥80% after the end of the EVT.
- Symptomatic intracranial hemorrhage after the end of EVT procedure.
- Any medical condition where randomization to either standard or intensive BP lowering would not be acceptable at the discretion of the investigators and/or the treating physician.
- Pregnancy.
- Enrollment in another acute stroke therapeutic trial.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Intensive Blood Pressure management
Participants assigned to the intensive blood pressure management arm will be treated using approved antihypertensive medications to have systolic blood pressure readings under 140 mmHg for the first 48 hours after enrollment into the study.
|
10 - 20 mg IV q15 minutes PRN until systolic BP below target (max 300 mg per 24 hours)
10 - 20 mg IV bolus q20 min until systolic BP below target (max 240 mg per 24 hours)
1.25 - 2.5 mg IV bolus and then q6h PRN.
|
|
Active Comparator: Standard Blood Pressure management
Participants assigned to the standard blood pressure management arm will be treated using approved antihypertensive medications to have systolic blood pressure readings under 180 mmHg for the first 48 hours after enrollment into the study.
|
10 - 20 mg IV q15 minutes PRN until systolic BP below target (max 300 mg per 24 hours)
10 - 20 mg IV bolus q20 min until systolic BP below target (max 240 mg per 24 hours)
1.25 - 2.5 mg IV bolus and then q6h PRN.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Mean enrollment rate.
Time Frame: through study completion, an average of 18 months
|
The predefined target is to achieve a mean enrollment rate of 2 patients per month.
|
through study completion, an average of 18 months
|
|
Number of participants with treatment allocation change.
Time Frame: 48 hours from treatment initiation
|
The predefined target is that at least 80% of the participants remain within their assigned treatment group, and not changing treatment allocation for any reason.
|
48 hours from treatment initiation
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Number of participants with any intracranial hemorrhage.
Time Frame: 24±12 hours from treatment initiation
|
As identified in the follow-up computed tomography scan.
|
24±12 hours from treatment initiation
|
|
Absolute difference in flow velocity measurements in transcranial Doppler.
Time Frame: 0-18 hours from treatment initiation
|
Assessed with the adjusted mean flow velocities of the recanalized vessel on transcranial Doppler examination.
|
0-18 hours from treatment initiation
|
|
Absolute difference in the NIH Stroke Scale change at day 1.
Time Frame: 24±12 hours from treatment initiation
|
NIH Stroke Scale ranges from 0 to 42, with higher scores indicating more severe impairment caused by a stroke.
|
24±12 hours from treatment initiation
|
|
Absolute difference in the NIH Stroke Scale change at day 2.
Time Frame: 48±12 hours from treatment initiation
|
NIH Stroke Scale ranges from 0 to 42, with higher scores indicating more severe impairment caused by a stroke.
|
48±12 hours from treatment initiation
|
Other Outcome Measures
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Absolute difference in mean systolic blood pressure values.
Time Frame: 48 hours from treatment initiation
|
Difference in mean systolic blood pressure values between the two arms.
|
48 hours from treatment initiation
|
|
Number of participants with symptomatic intracranial hemorrhage.
Time Frame: 24±12 hours from treatment initiation
|
According to the Safe Implementation of Thrombolysis in Stroke-Monitoring Study (SITS-MOST), National Institute of Neurological Disorders and Stroke (NINDS) and European-Australian Cooperative Acute Stroke Study 2 (ECASS 2) definitions.
|
24±12 hours from treatment initiation
|
|
Number of deaths during hospitalization.
Time Frame: Day 7 from treatment initiation or hospital discharge
|
All-cause in-hospital mortality.
|
Day 7 from treatment initiation or hospital discharge
|
|
Number of deaths during follow-up.
Time Frame: Day 90±10 from treatment initiation
|
All-cause mortality.
|
Day 90±10 from treatment initiation
|
|
Number of participants with neurological deterioration.
Time Frame: 24 hours from treatment initiation
|
Defined as ≥4 points decline in the National Institute of Health Stroke Scale (NIHSS) from randomization or death.
|
24 hours from treatment initiation
|
|
Functional outcome during hospitalization.
Time Frame: Day 7 from treatment initiation or hospital discharge
|
Ordinal shift analysis of the full range of category scores (0-6) of the modified Rankin Scale (mRS).
|
Day 7 from treatment initiation or hospital discharge
|
|
Functional outcome during follow-up.
Time Frame: Day 90±10 from treatment initiation
|
Ordinal shift analysis of the full range of category scores (0-6) of the modified Rankin Scale (mRS).
|
Day 90±10 from treatment initiation
|
|
Number of participants with favorable functional outcomes during hospitalization.
Time Frame: Day 7 from treatment initiation or hospital discharge
|
Favorable functional outcomes defined as modified Rankin Scale (mRS) scores of 0-1 or 0-2.
|
Day 7 from treatment initiation or hospital discharge
|
|
Number of participants with favorable functional outcomes during follow-up
Time Frame: Day 90±10 from treatment initiation
|
Favorable functional outcomes defined as modified Rankin Scale (mRS) scores of 0-1 or 0-2.
|
Day 90±10 from treatment initiation
|
|
Absolute difference in the decline of the Alberta stroke program early CT scores.
Time Frame: 24±12 hours from treatment initiation
|
The Alberta Stroke Program Early CT Score (ASPECTS) is a 10-point (range 0-10) quantitative topographic imaging scale with higher scores indicating more favorable imaging profiles.
Differences will be assessed between the baseline and repeat computed tomography scan.
|
24±12 hours from treatment initiation
|
|
Absolute difference in final infarct volumes.
Time Frame: Day 7 from treatment initiation
|
As assessed in the magnetic resonance imaging (MRI) scan, when available.
|
Day 7 from treatment initiation
|
|
Absolute difference in hospital stay.
Time Frame: Day 7 from treatment initiation or hospital discharge
|
Duration of hospital length of stay in days.
|
Day 7 from treatment initiation or hospital discharge
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Aristeidis H Katsanos, MD, Hamilton General Hospital, Hamilton Health Sciences
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Cardiovascular Diseases
- Vascular Diseases
- Cerebrovascular Disorders
- Brain Diseases
- Central Nervous System Diseases
- Nervous System Diseases
- Stroke
- Physiological Effects of Drugs
- Adrenergic beta-Antagonists
- Adrenergic Antagonists
- Adrenergic Agents
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Antihypertensive Agents
- Vasodilator Agents
- Autonomic Agents
- Peripheral Nervous System Agents
- Enzyme Inhibitors
- Protease Inhibitors
- Angiotensin-Converting Enzyme Inhibitors
- Sympathomimetics
- Adrenergic alpha-1 Receptor Antagonists
- Adrenergic alpha-Antagonists
- Enalapril
- Labetalol
- Hydralazine
Other Study ID Numbers
Other Study ID Numbers
- DETECT-v1.0
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.